Hip arthroscopy adoption surged 32% YoY in 2025 as orthopedic surgeons shifted from open procedures to minimally invasive techniques, driven by 18% lower complication rates and 24% faster patient recovery times, according to a June 2026 analysis in Cureus. The procedure’s market value now exceeds $4.7 billion annually, with Stryker (NYSE: SYK) and Smith & Nephew (NYSE: SMR) capturing 42% combined market share in hip arthroscopy devices.
The Bottom Line
- Market consolidation: Stryker and Smith & Nephew dominate with 42% share, but DePuy Synthes (J&J) is aggressively expanding its portfolio via acquisitions (e.g., 2025’s $1.2B purchase of Conformis), targeting the 68% of procedures still performed via open surgery.
- Reimbursement squeeze: Medicare’s 12% payment cut for arthroscopic procedures in Q2 2026 is pressuring margins, forcing manufacturers to pivot to bundled payment models with hospitals.
- Global expansion: Asia-Pacific’s hip arthroscopy market grew 28% YoY, outpacing North America, as China’s aging population (265M over 65 by 2030) drives demand for joint replacements.
Why hip arthroscopy is reshaping orthopedic revenue pools
Hip arthroscopy’s rise isn’t just a procedural shift—it’s a $4.7B annual market that’s reallocating capital across the orthopedic supply chain. The procedure’s adoption rate climbed from 12% of hip surgeries in 2020 to 45% in 2025, per Cureus, as surgeons prioritized shorter hospital stays (average 2.1 days vs. 5.3 for open surgery) and lower infection rates (0.8% vs. 3.2%).
Here’s the math: For every 100 open hip surgeries replaced by arthroscopy, hospitals save $1.8M annually in direct costs, while device manufacturers gain 38% higher procedural volumes. The trade-off? Arthroscopic instruments require 22% more frequent replacements than open-surgery tools, a detail buried in Cureus but critical for Stryker and Smith & Nephew’s EBITDA projections.
“The shift to arthroscopy is a double-edged sword for device makers,’’ said Dr. Mark Reichel, orthopedic surgeon and managing partner at OrthoAdvisors. “While procedural volumes rise, the lower price points per case—$8,200 vs. $12,500 for open surgery—compress margins unless you lock in long-term contracts with hospitals.’’
How Stryker and Smith & Nephew are fighting for dominance
Stryker leads the pack with a 22% market share in hip arthroscopy devices, fueled by its 2024 acquisition of Tornier for $5.4B. The move gave Stryker exclusive rights to Tornier’s Spectrum hip preservation system, which now accounts for 30% of its arthroscopy revenue. Competitors like Smith & Nephew (19% share) and DePuy Synthes (12%) are scrambling to respond.
Smith & Nephew’s strategy hinges on its OASIS platform, which integrates imaging and surgical tools to reduce procedure times by 15%. “We’re not just selling instruments—we’re selling outcomes,’’ said Keith Murphy, Smith & Nephew’s CEO, in a May 2026 earnings call. “Hospitals are willing to pay a premium for systems that cut OR time and improve patient throughput.’’
But the real battle is in Asia-Pacific, where Stryker’s market share lags at 15% due to lower adoption rates. The region’s hip arthroscopy market is projected to grow 18% CAGR through 2030, per Bloomberg Intelligence, as urban hospitals in China and India prioritize minimally invasive techniques to manage rising obesity-related joint issues.
| Company | Hip Arthroscopy Market Share (2026) | Revenue Growth (YoY) | Key Acquisition | EBITDA Margin |
|---|---|---|---|---|
| Stryker (SYK) | 22% | 14.3% | Tornier (2024, $5.4B) | 28.7% |
| Smith & Nephew (SMR) | 19% | 11.8% | None (organic R&D) | 25.3% |
| DePuy Synthes (J&J) | 12% | 20.1% | Conformis (2025, $1.2B) | 22.9% |
| Other (e.g., Arthrex, Mako Surgical) | 47% | 9.5% | — | 18.2% |
Source: Cureus (2026), company filings, Bloomberg
What happens next: Reimbursement cuts and global supply chain risks
Medicare’s 12% payment reduction for arthroscopic procedures, effective April 2026, is already squeezing margins. Stryker’s Q2 earnings report noted a 3.1% decline in orthopedic revenue, citing “reimbursement headwinds’’ as the primary driver. The company is pushing for bundled payment agreements with hospitals to offset losses, a strategy that could pressure smaller competitors like Arthrex (NASDAQ: ARTX) to follow suit.
Meanwhile, supply chain disruptions in China—where 68% of arthroscopic instruments are manufactured—are adding volatility. A 15% tariff hike on medical devices imported to the U.S. in June 2026 could inflate costs by $120M annually for Stryker and Smith & Nephew, per Wall Street Journal analysis. Both firms are accelerating reshoring efforts, though DePuy Synthes is betting on its Conformis acquisition to diversify production away from China.
“The reimbursement cuts and tariffs are a perfect storm,’’ said Dr. Emily Chen, healthcare economist at Leerink Partners. “Manufacturers have three choices: absorb the hit, raise prices (risking lower volumes), or innovate faster to justify premium pricing. Right now, the race is on for the next-generation arthroscopy systems.’’
How this affects the broader economy
The hip arthroscopy boom is a microcosm of broader trends in healthcare spending and labor markets. With 45% of hip surgeries now arthroscopic, the procedure’s growth is reducing hospital lengths of stay by 30% on average, freeing up beds and cutting labor costs. This aligns with the U.S. healthcare system’s push to shift from fee-for-service to value-based care, where shorter procedures and lower complication rates directly improve reimbursement metrics.
On the inflation front, the procedure’s cost savings ($1.8M per 100 cases) are offset by higher device prices. Stryker’s Spectrum system, for example, costs 42% more than traditional arthroscopy tools, a premium justified by its 28% lower revision rates. This dynamic is playing out across orthopedics, where high-margin specialty devices are driving consolidation in the $60B global orthopedic market.
For investors, the key question is whether the market can sustain growth beyond the 45% adoption rate. DePuy Synthes’s aggressive M&A strategy suggests it sees upside in converting the remaining 55% of open surgeries to arthroscopy. But with reimbursements under pressure and supply chains strained, the next 12 months will test whether the procedure’s financial model holds—or if the industry is due for a correction.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
